Akero Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKRO and other ETFs, options, and stocks.About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
CEOAndrew Cheng
CEOAndrew Cheng
Employees63
Employees63
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees63
Employees63
AKRO Key Statistics
Market cap4.33B
Market cap4.33B
Price-Earnings ratio-12.23
Price-Earnings ratio-12.23
Dividend yield—
Dividend yield—
Average volume990.19K
Average volume990.19K
High today$55.70
High today$55.70
Low today$54.08
Low today$54.08
Open price$54.55
Open price$54.55
Volume29.30M
Volume29.30M
52 Week high$58.40
52 Week high$58.40
52 Week low$21.34
52 Week low$21.34
AKRO News
Nasdaq 7h
Novo Nordisk To Acquire Akero Therapeutics; Akero Shareholders To Receive $54/Shr, CVR Of $6/Shr(RTTNews) - Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, Inc., a publicly held clinicalstage company developing treatment...
Analyst ratings
89%
of 9 ratingsBuy
88.9%
Hold
11.1%
Sell
0%
People also own
Based on the portfolios of people who own AKRO. This list is generated using Robinhood data, and it’s not a recommendation.